Balance Sheet

Accounts Payables Accumulated Expenses Assets Capital Leases Cash & Current Investments Cash & Equivalents Common Equity Convertible Debt Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Leases Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deffered Revenue Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Pension Preferred Shares Prepaid Assets Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Daily Values

Growth Metrics

Others

Supernus Pharmaceuticals (SUPN) Long-Term Deferred Tax (2016 - 2025)

Historic Long-Term Deferred Tax for Supernus Pharmaceuticals (SUPN) over the last 6 years, with Q3 2025 value amounting to $8.8 million.

Supernus Pharmaceuticals' Long-Term Deferred Tax changed N/A to $8.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.8 million, marking a year-over-year change of. This contributed to the annual value of $32.1 million for FY2019, which is 801.81% up from last year.
Latest data reveals that Supernus Pharmaceuticals reported Long-Term Deferred Tax of $8.8 million as of Q3 2025.
Supernus Pharmaceuticals' 5-year Long-Term Deferred Tax high stood at $8.8 million for Q3 2025, and its period low was $6.2 million during Q2 2025.